Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies
Precision oncology is predicated upon the ability to detect specific actionable genomic alterations and to monitor their adaptive evolution during treatment to counter resistance. Because of spatial and temporal heterogeneity and comorbidities associated with obtaining tumor tissues, especially in t...
Uloženo v:
| Vydáno v: | Molecular cancer research Ročník 14; číslo 10; s. 898 - 908 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.10.2016
|
| Témata: | |
| ISSN: | 1557-3125 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Precision oncology is predicated upon the ability to detect specific actionable genomic alterations and to monitor their adaptive evolution during treatment to counter resistance. Because of spatial and temporal heterogeneity and comorbidities associated with obtaining tumor tissues, especially in the case of metastatic disease, traditional methods for tumor sampling are impractical for this application. Known to be present in the blood of cancer patients for decades, cell-free DNA (cfDNA) is beginning to inform on tumor genetics, tumor burden, and mechanisms of progression and drug resistance. This substrate is amenable for inexpensive noninvasive testing and thus presents a viable approach to serial sampling for screening and monitoring tumor progression. The fragmentation, low yield, and variable admixture of normal DNA present formidable technical challenges for realization of this potential. This review summarizes the history of cfDNA discovery, its biological properties, and explores emerging technologies for clinically relevant sequence-based analysis of cfDNA in cancer patients. Molecular barcoding (or Unique Molecular Identifier, UMI)-based methods currently appear to offer an optimal balance between sensitivity, flexibility, and cost and constitute a promising approach for clinically relevant assays for near real-time monitoring of treatment-induced mutational adaptations to guide evidence-based precision oncology. Mol Cancer Res; 14(10); 898-908. ©2016 AACR. |
|---|---|
| AbstractList | Precision oncology is predicated upon the ability to detect specific actionable genomic alterations and to monitor their adaptive evolution during treatment to counter resistance. Because of spatial and temporal heterogeneity and comorbidities associated with obtaining tumor tissues, especially in the case of metastatic disease, traditional methods for tumor sampling are impractical for this application. Known to be present in the blood of cancer patients for decades, cell-free DNA (cfDNA) is beginning to inform on tumor genetics, tumor burden, and mechanisms of progression and drug resistance. This substrate is amenable for inexpensive noninvasive testing and thus presents a viable approach to serial sampling for screening and monitoring tumor progression. The fragmentation, low yield, and variable admixture of normal DNA present formidable technical challenges for realization of this potential. This review summarizes the history of cfDNA discovery, its biological properties, and explores emerging technologies for clinically relevant sequence-based analysis of cfDNA in cancer patients. Molecular barcoding (or Unique Molecular Identifier, UMI)-based methods currently appear to offer an optimal balance between sensitivity, flexibility, and cost and constitute a promising approach for clinically relevant assays for near real-time monitoring of treatment-induced mutational adaptations to guide evidence-based precision oncology. Mol Cancer Res; 14(10); 898-908. ©2016 AACR. |
| Author | Morin, Ryan D Volik, Stanislav Alcaide, Miguel Collins, Colin |
| Author_xml | – sequence: 1 givenname: Stanislav surname: Volik fullname: Volik, Stanislav organization: Vancouver Prostate Centre, Vancouver, British Columbia, Canada – sequence: 2 givenname: Miguel surname: Alcaide fullname: Alcaide, Miguel organization: Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada – sequence: 3 givenname: Ryan D surname: Morin fullname: Morin, Ryan D email: rmorin@bcgsc.ca, ccollins@prostatecentre.com organization: Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada. Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada. rmorin@bcgsc.ca ccollins@prostatecentre.com – sequence: 4 givenname: Colin surname: Collins fullname: Collins, Colin email: rmorin@bcgsc.ca, ccollins@prostatecentre.com organization: Vancouver Prostate Centre, Vancouver, British Columbia, Canada. Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. rmorin@bcgsc.ca ccollins@prostatecentre.com |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27422709$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1UEtPwzAYixCIPeAngHIch4wkzaPlNsp4SBMctp2rJP2yBbXpaLvD_j1FwMmWZdmyJ-g8NhEQumF0zphM75kUjGidqnntWsIUoVSIMzRmUmqSMC5HaNJ1n5RyyrS6RCOuBeeaZmNkc6gq4lsA_PS-wDPnB7h7wHkVYnCmwuuwi8EPNDrAJpZ424cq9CccIs5_xBav9-YAJX484WUN7S7EHd6A28emanYBuit04U3VwfUfTtH2ebnJX8nq4-UtX6yIS7TsSSl9KpPUa-qsBSUkd4mwJvGlcZCBh0wkRvhESaWYhYz7MtGWCisyL7RRfIpmv7mHtvk6QtcXdejcMM9EaI5dwVKuNB8q6GC9_bMebQ1lcWhDbdpT8f8L_warM2UP |
| CitedBy_id | crossref_primary_10_1371_journal_pntd_0008147 crossref_primary_10_1016_j_critrevonc_2022_103865 crossref_primary_10_1016_j_jmoldx_2021_08_014 crossref_primary_10_1016_j_wneu_2022_11_012 crossref_primary_10_3390_bios10110156 crossref_primary_10_3389_fphys_2019_01476 crossref_primary_10_1007_s10620_020_06209_2 crossref_primary_10_1186_s12864_019_5583_7 crossref_primary_10_3390_biomedicines10020506 crossref_primary_10_1002_VIW_20200118 crossref_primary_10_1177_1559325819891010 crossref_primary_10_1111_1759_7714_13418 crossref_primary_10_3390_life12111714 crossref_primary_10_3389_fmolb_2020_00113 crossref_primary_10_1158_1078_0432_CCR_21_0002 crossref_primary_10_7717_peerj_7426 crossref_primary_10_1038_s41467_021_22901_x crossref_primary_10_1016_j_prp_2025_156038 crossref_primary_10_1371_journal_pone_0253687 crossref_primary_10_1186_s12885_020_6562_8 crossref_primary_10_1186_s12885_020_07161_0 crossref_primary_10_1016_j_cancergen_2021_08_005 crossref_primary_10_1186_s13059_024_03456_8 crossref_primary_10_1158_1078_0432_CCR_18_0101 crossref_primary_10_1373_clinchem_2018_291278 crossref_primary_10_1093_bib_bbaa060 crossref_primary_10_1373_clinchem_2017_285668 crossref_primary_10_1016_j_yamp_2024_06_005 crossref_primary_10_1016_j_ctrv_2018_03_007 crossref_primary_10_1016_j_ihj_2023_01_011 crossref_primary_10_1186_s12967_023_04099_2 crossref_primary_10_3390_ijms19092568 crossref_primary_10_3390_ijms23084441 crossref_primary_10_1186_s12859_018_2428_3 crossref_primary_10_1038_s41598_020_78766_5 crossref_primary_10_3389_fmed_2020_594900 crossref_primary_10_1039_C7AN01965C crossref_primary_10_3390_encyclopedia1030044 crossref_primary_10_1007_s00412_021_00766_9 crossref_primary_10_1246_cl_210066 crossref_primary_10_1016_j_jmoldx_2018_09_007 crossref_primary_10_1016_j_cancergen_2019_04_062 crossref_primary_10_1111_febs_14601 crossref_primary_10_3892_ol_2024_14681 crossref_primary_10_1007_s13402_018_0413_5 crossref_primary_10_1038_s41598_019_41215_z crossref_primary_10_3390_mi9080397 crossref_primary_10_3390_chemosensors5040030 crossref_primary_10_3390_metabo15040227 crossref_primary_10_3389_fnmol_2017_00276 crossref_primary_10_1016_j_prnil_2022_07_002 crossref_primary_10_1073_pnas_2319634121 crossref_primary_10_1016_j_bios_2019_03_018 crossref_primary_10_1016_j_clgc_2024_102235 crossref_primary_10_3390_ijms24129981 crossref_primary_10_1038_s41598_018_36470_5 crossref_primary_10_1111_ajt_15822 crossref_primary_10_1016_j_currproblcancer_2020_100685 crossref_primary_10_1016_j_nantod_2022_101746 crossref_primary_10_1093_ajcp_aqac024 crossref_primary_10_3390_mi10100672 crossref_primary_10_1093_infdis_jiaf147 crossref_primary_10_1093_jnci_djx118 crossref_primary_10_1016_j_cgh_2020_08_065 crossref_primary_10_1016_j_euf_2016_12_006 crossref_primary_10_3389_fonc_2019_00317 crossref_primary_10_1007_s00247_017_3958_y crossref_primary_10_1038_s41698_024_00526_9 crossref_primary_10_1371_journal_pone_0243781 crossref_primary_10_3390_ijms23179521 crossref_primary_10_1002_cac2_12118 crossref_primary_10_1371_journal_pone_0253401 crossref_primary_10_1186_s13148_021_01182_7 crossref_primary_10_1080_14737159_2018_1407243 crossref_primary_10_1158_1078_0432_CCR_19_0152 crossref_primary_10_1016_j_saa_2020_119039 crossref_primary_10_1038_gt_2017_77 crossref_primary_10_1016_j_breast_2022_02_002 crossref_primary_10_1373_clinchem_2017_272559 crossref_primary_10_1016_j_pmu_2017_04_002 crossref_primary_10_3390_genes13040590 crossref_primary_10_3390_cancers13020346 crossref_primary_10_3390_cimb46070390 crossref_primary_10_3389_fonc_2021_666937 crossref_primary_10_1186_s13148_020_00999_y crossref_primary_10_3390_cancers11060805 crossref_primary_10_1002_adma_202505208 crossref_primary_10_1007_s11356_022_18828_5 crossref_primary_10_1111_trf_15242 crossref_primary_10_1093_infdis_jiad186 crossref_primary_10_1128_JCM_01061_18 crossref_primary_10_1016_j_bios_2024_116199 crossref_primary_10_1016_j_transproceed_2020_07_013 crossref_primary_10_3389_fonc_2022_958673 crossref_primary_10_1016_j_csbj_2021_12_001 crossref_primary_10_1016_j_surge_2021_06_006 crossref_primary_10_2174_0113816128328459241009191933 crossref_primary_10_3390_cancers17030357 crossref_primary_10_3390_genes14101884 crossref_primary_10_3390_bios13030380 crossref_primary_10_3390_app12146928 crossref_primary_10_3892_ol_2018_9198 crossref_primary_10_1007_s00414_025_03590_3 crossref_primary_10_1080_14737159_2019_1665508 crossref_primary_10_3390_cancers13143443 crossref_primary_10_1080_14737159_2019_1684265 crossref_primary_10_3390_ijms21239083 crossref_primary_10_3389_fbioe_2020_581157 crossref_primary_10_1080_17460441_2018_1479740 crossref_primary_10_1016_j_urolonc_2017_11_017 crossref_primary_10_1007_s13206_020_4208_1 crossref_primary_10_1002_pd_6092 crossref_primary_10_1038_s41431_018_0132_4 crossref_primary_10_1158_1078_0432_CCR_19_2533 crossref_primary_10_3390_pathogens10111524 crossref_primary_10_1093_nar_gkae736 crossref_primary_10_3389_fmed_2016_00069 crossref_primary_10_1016_j_eururo_2018_12_042 crossref_primary_10_1177_11782234241310596 crossref_primary_10_3390_cancers11121916 crossref_primary_10_1016_j_omtn_2020_12_017 crossref_primary_10_1016_j_parkreldis_2025_107919 crossref_primary_10_1038_s41598_017_10269_2 crossref_primary_10_1186_s13046_018_0893_1 crossref_primary_10_3389_fonc_2021_800053 crossref_primary_10_1038_s41598_017_06106_1 crossref_primary_10_3390_cells12030413 crossref_primary_10_1159_000515522 crossref_primary_10_3390_cancers13143460 crossref_primary_10_3390_pathogens12030394 crossref_primary_10_3390_ijms24065411 crossref_primary_10_1155_2018_7392419 crossref_primary_10_1016_j_cjac_2021_05_002 crossref_primary_10_1186_s12885_020_07445_5 crossref_primary_10_1002_cbin_11286 crossref_primary_10_3390_cancers15020431 crossref_primary_10_1016_j_trsl_2022_12_006 crossref_primary_10_1016_j_critrevonc_2019_102827 crossref_primary_10_1016_j_heliyon_2022_e11022 crossref_primary_10_1002_gcc_22734 crossref_primary_10_1007_s12010_018_2858_4 crossref_primary_10_1016_j_actbio_2022_04_046 crossref_primary_10_3390_cancers14030743 crossref_primary_10_1016_j_adcanc_2022_100052 crossref_primary_10_1002_btm2_10348 crossref_primary_10_1002_jcph_934 crossref_primary_10_1016_j_canrad_2017_08_105 crossref_primary_10_3390_cancers11121938 crossref_primary_10_1016_j_cancergen_2020_12_006 crossref_primary_10_1016_j_bpj_2025_05_028 crossref_primary_10_1016_j_semcancer_2019_12_014 crossref_primary_10_1089_bio_2019_0026 crossref_primary_10_1136_bmjopen_2024_086648 crossref_primary_10_1038_s41598_020_74288_2 crossref_primary_10_3390_cells8111459 crossref_primary_10_1016_j_snb_2024_135363 crossref_primary_10_1016_j_euf_2022_09_002 crossref_primary_10_3390_biom13091418 crossref_primary_10_1002_ctm2_1652 crossref_primary_10_1246_bcsj_20200235 crossref_primary_10_1016_j_jmoldx_2017_10_007 crossref_primary_10_1016_j_fsigen_2024_103210 crossref_primary_10_1097_PPO_0000000000000311 crossref_primary_10_1016_j_cej_2025_161435 crossref_primary_10_3390_cancers14020288 crossref_primary_10_1002_ijc_32206 crossref_primary_10_3390_metabo15040244 crossref_primary_10_1016_j_saa_2024_123897 crossref_primary_10_3390_cancers15051433 crossref_primary_10_47248_chp2502030014 crossref_primary_10_1038_s41585_019_0261_8 crossref_primary_10_1097_CMR_0000000000000432 crossref_primary_10_4103_tcmj_tcmj_191_23 crossref_primary_10_1016_j_trac_2022_116897 crossref_primary_10_1002_slct_201802671 crossref_primary_10_1093_infdis_jiae462 crossref_primary_10_3390_ijms21186827 crossref_primary_10_1038_s41598_023_42726_6 crossref_primary_10_1186_s12867_017_0098_8 crossref_primary_10_3389_fgene_2021_654887 crossref_primary_10_1038_s41388_020_1327_z crossref_primary_10_1080_00365521_2017_1301989 crossref_primary_10_1007_s13205_025_04272_y crossref_primary_10_1038_s41598_023_46663_2 crossref_primary_10_1080_14737159_2023_2178903 crossref_primary_10_1186_s12967_023_04160_0 crossref_primary_10_1016_j_bios_2023_115611 crossref_primary_10_3103_S0027131421060079 crossref_primary_10_3390_diagnostics12051192 crossref_primary_10_1016_j_cca_2020_01_013 crossref_primary_10_1038_s41598_020_72163_8 crossref_primary_10_1016_j_ejca_2021_05_039 crossref_primary_10_1016_j_mgene_2018_06_013 crossref_primary_10_1093_clinchem_hvaf064 crossref_primary_10_4103_jcrt_JCRT_415_20 crossref_primary_10_1016_j_mrrev_2019_05_002 crossref_primary_10_1016_j_bbrc_2018_07_037 crossref_primary_10_1038_s41525_018_0072_5 crossref_primary_10_1038_s41698_018_0072_z crossref_primary_10_1158_1078_0432_CCR_19_3005 crossref_primary_10_1007_s13167_018_0147_5 crossref_primary_10_3389_fcimb_2025_1504262 crossref_primary_10_1200_GO_20_00651 crossref_primary_10_3389_fmicb_2024_1413532 crossref_primary_10_1007_s10238_023_01278_9 crossref_primary_10_1007_s12031_025_02317_8 crossref_primary_10_3390_biom10030415 crossref_primary_10_3390_diagnostics13020208 crossref_primary_10_1186_s12935_024_03600_1 crossref_primary_10_1016_j_jmoldx_2019_03_006 crossref_primary_10_1186_s40580_018_0170_1 crossref_primary_10_3390_molecules25030490 crossref_primary_10_1002_path_5157 crossref_primary_10_1158_1078_0432_CCR_21_2199 crossref_primary_10_1093_annonc_mdx288 crossref_primary_10_1038_s41598_020_69432_x crossref_primary_10_1177_03000605241302302 crossref_primary_10_3171_2019_9_FOCUS19712 crossref_primary_10_3390_cancers17132229 |
| ContentType | Journal Article |
| Copyright | 2016 American Association for Cancer Research. |
| Copyright_xml | – notice: 2016 American Association for Cancer Research. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1158/1541-7786.mcr-16-0044 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1557-3125 |
| EndPage | 908 |
| ExternalDocumentID | 27422709 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: CIHR |
| GroupedDBID | --- .55 .GJ 123 18M 2FS 2WC 34G 39C 3O- 53G 5RE 5VS AAJMC ABEFU ACGFO ACPRK ADBBV ADCOW AENEX AFFNX AFHIN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW C1A CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P GX1 H13 HH5 H~9 IH2 KQ8 L7B MVM NPM OK1 QTD RCR RHI TR2 W8F WHG WOQ X7M YKV ZGI 7X8 |
| ID | FETCH-LOGICAL-c375t-d5f8538f70cbbe6452c34ba3fdace9efe943a4f365661be92fd37b04b49f47a62 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 279 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000386590200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| IngestDate | Sun Nov 09 14:08:53 EST 2025 Mon Jul 21 05:54:37 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| License | 2016 American Association for Cancer Research. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c375t-d5f8538f70cbbe6452c34ba3fdace9efe943a4f365661be92fd37b04b49f47a62 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| PMID | 27422709 |
| PQID | 1826725380 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_1826725380 pubmed_primary_27422709 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-10-00 20161001 |
| PublicationDateYYYYMMDD | 2016-10-01 |
| PublicationDate_xml | – month: 10 year: 2016 text: 2016-10-00 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Molecular cancer research |
| PublicationTitleAlternate | Mol Cancer Res |
| PublicationYear | 2016 |
| SSID | ssj0020176 |
| Score | 2.6077952 |
| SecondaryResourceType | review_article |
| Snippet | Precision oncology is predicated upon the ability to detect specific actionable genomic alterations and to monitor their adaptive evolution during treatment to... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 898 |
| SubjectTerms | Cell-Free System Disease Progression DNA, Neoplasm - blood Humans Neoplasms - genetics Precision Medicine |
| Title | Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27422709 https://www.proquest.com/docview/1826725380 |
| Volume | 14 |
| WOSCitedRecordID | wos000386590200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Pa9swFBbd2o1d2jXrumztUGGH7qBFjhRL6mWkaUsvCYEskFvQr7cGMidL0kH---nZbnsaDHqwDQaDkZ6kT-_79D5CvvAQtBfWMZ7ABZMaBLPgUWCTgZUhXVGXZhNqMNCTiRnWCbd1Lat8mBPLiTosPObIW4iDVTsNT_59-ZuhaxSyq7WFxguyKxKUQUmXmjyyCGltU3l9aifr6FZCCxnDemnffvkVy9JOmkv5b2RZrjA3B8_9t7dkv8aWtFsFwyHZiUWDvKrcJrcN8rpf8-jviOvF-ZzBKkZ6NejScw_p8fWC1lVC53Q0-1mgiAhjgtoi0PEGRbRbOitoD1-u6OjOLmOgl1uKiS30OqKPefq0_T4i45vrH71bVrstMC9UZ8NCB9LSrUFx71xEvtML6ayAYH00EaKRwkoQCAAzF00bglCOSycNSGXz9nvyslgU8QOhWukOBB4gyLIemzGgdZ4rkEHzYFyTnD204zRFM1IUtoiL-_X0qSWb5LjqjOmyKrsxRVK5rbj5-B9ffyJvUu_nleruhOxCGsvxlOz5P5vZevW5DJN0Hwz7fwE6t8dy |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cell-free+DNA+%28cfDNA%29%3A+Clinical+Significance+and+Utility+in+Cancer+Shaped+By+Emerging+Technologies&rft.jtitle=Molecular+cancer+research&rft.au=Volik%2C+Stanislav&rft.au=Alcaide%2C+Miguel&rft.au=Morin%2C+Ryan+D&rft.au=Collins%2C+Colin&rft.date=2016-10-01&rft.eissn=1557-3125&rft.volume=14&rft.issue=10&rft.spage=898&rft_id=info:doi/10.1158%2F1541-7786.mcr-16-0044&rft_id=info%3Apmid%2F27422709&rft_id=info%3Apmid%2F27422709&rft.externalDocID=27422709 |